---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000864"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:03:01.221890+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement

## Summary
- Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.
- R&D expenses rose to $1.0M (from $0.7M) on increased manufacturing costs for paridiprubart.
- Cash at Dec 31, 2024 was $1.6M; subsequent $15M preferred/common private placement closed.
- Company plans IND for EB06 (anti-CXCL10) in vitiligo Phase 2; FDA submission mid-2025.
- EB05 (paridiprubart) ARDS study fully funded by U.S. government; top-line vitiligo data expected within 12-18 months post clearance.

## SEC filing metadata
- accession: 0001171843-25-000864
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325000864/0001171843-25-000864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325000864/f8k_021425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000864
- JSON: https://secwatch.observer/filing/0001171843-25-000864.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.